Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Phoenix & Scottsdale, AZ

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
610
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Phoenix & Scottsdale, AZ
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mayo Clinic, Phoenix & Scottsdale, AZ. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 277–288 of 610 matching trials with a site at Mayo Clinic, Phoenix & Scottsdale, AZ.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

NCT05245500
Status at this site: Recruiting
View directory record Official record
Conditions
Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
Interventions
MRTX1719
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Lone Tree, Colorado • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

NCT05506943
Site status not listed — check the official record
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
Interventions
CTX-009, Paclitaxel
Drug
Lead sponsor
Compass Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Active, not recruiting Phase 3 Interventional

Breast Cancer WEight Loss Study (BWEL Study)

NCT02750826
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Synchronous Bilateral Breast Carcinoma
Interventions
Health Education Program, Weight Loss Intervention
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
3,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1464
States / cities
Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 921 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Active, not recruiting Phase 2 Interventional

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial

NCT05247905
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma
Interventions
Lutetium Lu 177 Dotatate, Capecitabine, Temozolomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
171
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Beverly Hills, California + 135 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

NCT04930653
Status at this site: Suspended
View directory record Official record
Conditions
Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Transformed Mycosis Fungoides
Interventions
Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Recruiting Phase 2Phase 3 Interventional

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

NCT05174169
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Stage III Colon Cancer
Interventions
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
Device · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1037
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 723 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Active, not recruiting Not applicable Interventional

A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors

NCT06198010
Site status not listed — check the official record
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions
Best Practice, Educational Intervention, Questionnaire Administration, Electronic Health Record Review, Health Telemonitoring, Cancer Pain Management
Other · Procedure · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Recruiting Phase 3 Interventional

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

NCT06072612
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Interventions
SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
Biological · Drug
Lead sponsor
BriaCell Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Active, not recruiting Phase 2 Interventional

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

NCT07228390
Site status not listed — check the official record
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial

NCT06319248
Status at this site: Recruiting
View directory record Official record
Conditions
Sepsis, Low Blood Pressure
Interventions
Midodrine, Standard of Care
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

NCT05207670
Site status not listed — check the official record
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Mosunetuzumab (Cohorts A-C), Mosunetuzumab (Cohorts D-E), Tocilizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
39
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 20, 2026, 2:53 AM EDT
Not yet recruiting Phase 2 Interventional

Rimegepant For Endometriosis Pain

NCT07795125
Site status not listed — check the official record
View directory record Official record
Conditions
Endometriosis, Endometriosis-related Pain
Interventions
Rimegepant 75 MG, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 20, 2026, 2:53 AM EDT

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Phoenix & Scottsdale, AZ as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.